Statistics from Altmetric.com
Biomarkers are becoming increasingly important in distinguishing people with different dementias from older individuals without progressive cognitive decline,1 but their value in distinguishing between dementia subtypes is less clear. Dementia with Lewy-bodies (DLB) accounts for 10%–15% of people with dementia, and the complex combination of cognitive, neuropsychiatric, autonomic and motor disturbances results in greater impairment of quality of life, more carer burden, and higher health-related costs compared with other dementias.2 This, together with a high sensitivity to drug-related adverse events, in particular, antipsychotic agents, makes an early and accurate diagnosis imperative.
Dopamine transporter (DAT) scan, using ligands, such as beta-CIT, …
Contributors DA drafted the paper; CGB critically reviewed the paper. Both authors contributed to literature search and intellectual content.
Funding DA has received research support from GE Health.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.